Cefiderocol appears promising, as it can overcome most β-lactam resistance mechanisms
(including β-lactamases, porin mutations, and efflux pumps). Resistance is uncommon …

Resistance to β-lactam antibiotics is rapidly growing, substantially due to the spread of
serine-β-lactamases (SBLs) and metallo-β-lactamases (MBLs), which efficiently catalyse β …

Modern medicine is threatened by the rising tide of antimicrobial resistance, especially
among Gram-negative bacteria, where resistance to β-lactams is most often mediated by β …

Cefiderocol has been approved in the United States and Europe but not in China. We aim to
evaluate carbapenem-resistant Enterobacterales (CRE) susceptibility to cefiderocol to …

The rapid emergence of antimicrobial resistance (AMR) pathogens highlights the urgent
need to approach this global burden with alternative strategies. Cefiderocol (Fetroja®) is a …

Cefiderocol is a promising novel siderophore cephalosporin for the treatment of multidrug-
resistant Gram-negative bacilli and with stability against degradation by metallo-β …

Carbapenem-resistant Enterobacterales (CRE) remain a significant public health threat,
and, despite recent approvals, new antibiotics are needed. Severe infections caused by …

Cefiderocol is a novel siderophore cephalosporin exhibiting potent antimicrobial activities.
Although cefiderocol has not been approved in China, resistance is emerging. A multicenter …

Appropriate antibiotic treatment for critically ill patients with serious Gram-negative infections
in the intensive care unit is crucial to minimize morbidity and mortality. Several new …

Introduction The choice of best therapeutic strategy for difficult-to-treat resistance (DTR)
Gram-negative infections currently represents an unmet clinical need. Areas covered This …